cases

Indicate

between the groups.”

The authors report that a total of 29,802 procedures were included in their study population, with 82.7% receiving DAPT and 17.3% receiving an alternative antiplatelet regimen. Propensity-score matching generated 4,876 unique pairs across which they performed their analysis.

Compared with patients on DAPT, in-hospital ipsilateral stroke rates were “significantly higher” among those receiving other types of antiplatelet therapy (1.1% vs. 1.7%, respectively). And, while there was no statistically significant difference between the two groups regarding mortality—0.5% with DAPT and 0.6% without—a composite of stroke/death was more likely in patients receiving an alternative regimen (2.4%) rather than DAPT.

Furthermore, Dakour-Aridi, Wang and colleagues found that immediate stent thrombosis was more common in the ‘alternative’ group of patients, and a non-significant trend towards increased rates of returning to the operating room was observed as well.